

1 Performance of the TaqMan™ COVID-19 Pooling Kit for detection of SARS-CoV-2 in Asymptomatic and
2 Symptomatic populations at an Institution of Higher Education

3

4 Troy Ganz^a, Sarah Sanderson^a, Connor Baush^a, Melanie Mejia^a, Manoj Gandhi^b, Jared Auclair^{a#}.

5

6 ^a. Life Science Testing Center, Northeastern University, Burlington, MA, USA

7 ^b. Thermo Fisher Scientific, South San Francisco, CA, USA

8

9 **Running Head:** RT-qPCR Sensitivity for Pooled Asymptomatic Sars-CoV-2

10

11 Address correspondence to Jared Auclair, Ph.D., j.auclair@northeastern.edu

12 **Abstract:**

13 Clinical evidence for asymptomatic cases of coronavirus disease (COVID-19) has reinforced the
14 significance of effective surveillance testing programs. Quantitative reverse transcriptase polymerase
15 chain reaction (RT-qPCR) assays are considered the ‘gold standard’ for detection of severe acute
16 respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA. However, the labor and resource requirements
17 can be prohibitive with respect to large testing volumes associated with the pandemic. Pooled testing
18 algorithms may serve to increase testing capacity with more efficient resource utilization. Due to the
19 lack of carefully curated cohorts, there is limited evidence for the applicability of RT-PCR pooling in
20 asymptomatic COVID-19 cases. In this study, we compared the analytical sensitivity of the TaqMan™
21 SARS-CoV-2 Pooling Assay to detect one positive sample in a pool of five anterior nares swabs in
22 symptomatic and asymptomatic cohorts at an institute of higher education. Positive pools were
23 deconvoluted and each individual sample was retested using the TaqPath™ COVID-19 Combo Kit. Both
24 assays target the open reading frame (ORF) 1ab, nucleocapsid (N), and spike (S) gene of the strain that
25 originated in Wuhan, Hubei, China. Qualitative results demonstrated absolute agreement between
26 pooled and deconvoluted samples in both cohorts. Independent t-test performed on C_t shifts confirmed
27 an insignificant difference between cohorts with p-values of 0.306 (Orf1ab), 0.147 (N), and 0.052 (S). All
28 negative pools were correctly reported as negative. Thus, pooled PCR testing up to five samples is a valid
29 method for surveillance testing of students and staff in a university setting, especially when the
30 prevalence is expected to be low.

31 **Introduction:**

32 Efforts to mitigate the reproductive number (R_0) for the coronavirus disease 2019 (COVID-19) pandemic,
33 an emergent respiratory infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-
34 CoV-2), has been undermined by the potential for sustained transmission through pre-symptomatic,
35 paucisymptomatic (subclinical), and asymptomatic carriers [1]. Growing evidence from immunological
36 case studies and bioinformatic investigations have substantiated clinical diagnostic testing that have
37 reported insignificant variance in results among patients that differ in symptomology. Asymptomatic
38 patients have reportedly developed ground-glass opacities in lung tissue and significant adaptive
39 immune (IgG and IgM) responses, however cell-mediated immune response from asymptomatic cases
40 have shown to be less significant compared to symptomatic cases [2,3]. A recent investigation noted a
41 correlation between globally reported asymptomatic cases and a single nucleotide polymorphism (SNP)
42 in SARS-CoV-2 RNA at position 11083G>T translating to a phenylalanine mutation (L37F) on non-
43 structural protein 6 (NSP6) [4]. While a less severe immune response may be elicited in asymptomatic
44 cases, the replication mechanisms in these individuals remain intact, and this necessitates effective risk
45 management measures [5].

46 The analytical sensitivity of RT-qPCR has propelled its utility as the 'gold standard' to accurately detect
47 SARS-CoV-2 RNA from upper respiratory specimens (e.g., nasopharyngeal, anterior nares, and saliva);
48 however, the high-complexity format has merged with demands of a pandemic to generate severe
49 shortages in materials and technical personnel. A resurgence of interest in group testing, or sample
50 pooling, whereby the ratio of specimens to result is greater than one, has led investigators to optimize
51 protocols that would allow an increase in testing capacity without requiring additional resources [6].
52 Caveats include a linear loss of sensitivity with sample dilution, and, in hierarchical systems, disease
53 prevalence may determine efficiency as positive pools are deconvoluted to retest each patient

54 individually [7]. Nevertheless, sample pooling stands to provide an accurate and affordable method for
55 general population testing.

56 Since gaining USFDA emergency use authorization (EUA) for the TaqPath™ COVID-19 Combo Kit on
57 March 24, 2020, Thermo Fisher Scientific, Inc. has developed a specialized RT-qPCR testing kit with
58 enhanced sensitivity for the purposes of pooling up to five samples known as the TaqMan™ SARS-CoV-2
59 Pooling Assay. In the following study, we compared the sensitivity of the TaqMan™ assay to detect one
60 positive sample in a pool of five from 30 symptomatic and 30 asymptomatic individuals that were
61 previously characterized as positive using the TaqPath™ COVID-19 Combo Kit; 10 negative pools of five
62 were included as a control group.

63 **Methods:**

64 **Sample Collection, Storage, and Preanalytical Processing:**

65 The study was conducted at the Northeastern University COVID-19 response laboratory, the Life Science
66 Testing Center (LSTC; Burlington, MA, USA), which performs population testing for university affiliates.
67 Students on campus are required to test every three days while staff and faculty on campus test twice a
68 week. Affiliates attending campus are required to complete a daily wellness tracker, or a two-question
69 survey, that identifies whether they have experienced COVID-19 related symptoms or have been in close
70 contact with a positive COVID-19 case in the past 24 hours. Depending on the survey results, they are
71 directed to get tested at either the non-symptomatic site (Cabot Center), where observed self-collection
72 is performed, or the symptomatic site (Marino Center), where collection is performed by a healthcare
73 professional. Temperature checks and general symptom screening were performed by trained personnel
74 on the subjects at both sites to determine presence or absence of symptoms. Anterior nasal swabs
75 (polyester) are collected in 3 mL BD Vacutainer® (without additive) tubes and transported dry to the
76 LSTC facility. Upon logging into the laboratory information system (LIMS), 3 mL of viral transport media
77 (VTM; Redoxica, Little Rock, AR, USA) is added and the sample is shaken at 1000 rpm for 5 minutes.

78 Processed specimens are stable for <72 hours at 2-8°C. Positive samples are catalogued, split into three
79 aliquots, and stored indefinitely at -80°C. Depending on the site at which the samples are collected
80 (Cabot or Marino), this monitoring approach allows for curated cohorts of symptomatic or
81 asymptomatic cases.

82 **TaqMan™ SARS-CoV-2 Pooling Assay: Pooled Specimen RNA Extraction and RT-qPCR Setup**

83 Pools consisting of five samples were constructed from one positive sample and four negative samples.
84 Positive samples were selected at random from -80°C storage and thawed at 2-8°C. RNA extraction was
85 performed using 400 µL of combined sample volume using the MagMAX™ Viral/Pathogen II (MVP II)
86 Nucleic Acid Isolation Kit (Thermo Fisher Scientific, Waltham, MA, USA) by combining 10 µL of
87 Proteinase K, 80 µL of each sample (400 µL pooled volume), 550 µL of lysis buffer with RNA binding
88 beads, and 10 µL of MS2 phage extraction control to a single well of an Agilent 1 mL 96-well plate. The
89 plate was vortexed 2 minutes at 1050 rpm, incubated 5 minutes at 65°C, vortexed for 5 minutes at 1050
90 rpm, and incubated at room temperature on a magnetic stand. After waste aspiration, the beads
91 underwent three cycles of resuspension/aspiration in 1 mL wash buffer, 1 mL 80% ethanol, and 50 µL
92 elution buffer, respectively. RT-qPCR was performed using 17.5 µL of eluant added to 7.5 µL of reaction
93 mix that contained 6.25 µL TaqPath™ 1-Step RT-qPCR MM, CG (4X) and 1.25 µL TaqMan™ SARS-CoV-2
94 Pooling Multiplex Assay.

95 **TaqPath™ COVID-19 Combo Kit: Deconvoluted Specimen RNA Extraction and RT-qPCR Setup**

96 Pools that tested positive were deconvoluted and each of the five component specimens were repeated
97 using the TaqPath™ COVID-19 Combo Kit currently employed at the LSTC. Briefly, RNA extraction was
98 performed using the MVPII kit with 5 µL of Proteinase K, 200 µL sample, 275 µL lysis buffer with RNA
99 binding beads, and 5 µL MS2 phage extraction control. Wash procedure was performed using an Agilent
100 Bravo liquid handler (Agilent Technologies, Santa Clara, CA, USA) whereby, after initial shaking 2 minutes
101 at 1050 rpm and 5 minutes incubation at 65°C, the beads underwent three cycles of

102 resuspension/aspiration in 165 μ L wash buffer, 165 μ L 80% ethanol, and 50 μ L elution buffer,
103 respectively. RT-qPCR was performed using 10 μ L of eluate added to 15 μ L of reaction mix that
104 contained 6.25 μ L TaqPath™ 1-Step Multiplex Master Mix (No ROX™) (4x), 1.25 μ L COVID-19 Real Time
105 PCR Assay Multiplex, and 7.5 μ L Nuclease-free water.

106 **RT-qPCR Thermal Profile and Results Management**

107 Both, the TaqMan™ and TaqPath™, methods contain primers and probes that target the SARS-CoV-2
108 open reading frame (ORF) 1ab, nucleocapsid (N), and spike (S) genes as well as the MS2 phage
109 extraction control (reporter dyes FAM, VIC, ABY, and JUN, respectively). Thermal profile parameters for
110 both assays involved a 2-minute UNG incubation cycle at 25°C, a 10-minute reverse transcriptase
111 incubation cycle at 53°C, a 2-minute activation cycle at 95°C, and 40 cycles of a 3-second denaturation at
112 95°C followed by 30-second anneal/extension cycle at 60°C on Applied Biosystems™ 7500 Fast Dx Real-
113 Time PCR Instrument (Thermo Fisher Scientific, Waltham, MA, USA). Resulting threshold cycle (C_t) values
114 were extracted using COVID-19 Interpretive Software and analyzed using Microsoft Excel® and
115 GraphPad Prism version 9 for Windows (GraphPad Software, San Diego, CA, USA). Qualitative endpoints
116 set to determine target presence were $C_t \leq 37$ for SARS-CoV-2 genes and $C_t \leq 32$ for MS2 control; $\geq 2/3$
117 SARS-CoV-2 genes designated a positive result and 1/3 SARS-CoV-2 genes designated an indeterminate
118 result.

119 **Results:**

120 Average monthly prevalence estimates ranging August 2020 to April 2021 for the Cabot Center (non-
121 symptomatic) was 0.159% (CI.95 0.086-0.234%) and Marino Center (symptomatic) was 3.33% (CI.95
122 2.05-4.61%). Thirty samples from each of the two sites were used to generate 60 five-sample pools with
123 240 negative samples. Each of the 60 five-sample pools tested positive using the TaqMan™ pooling
124 method and statistical analysis was performed using the deconvoluted result. Average C_t values for the
125 pooled asymptomatic samples were 22.17 (CI.95 20.18-24.16), 22.66 (CI.95 20.76-24.57), and 23.15

126 (CI.95 21.13-25.17) and the deconvoluted asymptomatic samples were 20.64 (CI.95 18.59-22.68), 21.30
127 (CI.95 19.38-23.22), and 20.81 (CI.95 18.92-22.69) for the ORF1ab, N, and S genes, respectively (Figure1:
128 a, b, c). Average C_t values for the pooled symptomatic samples were 22.47 (CI.95 20.31-24.63), 23.31
129 (CI.95 21.19-25.44), and 24.01 (CI.95 21.15-26.87) and the deconvoluted symptomatic samples were
130 20.65 (CI.95 18.53-22.77), 21.70 (CI.95 19.60-23.80), and 21.17 (CI.95 18.63-23.71) for the ORF1ab, N,
131 and S genes, respectively (Figure1: d, e, f). Dependent t-test analysis comparing pooled to deconvoluted
132 data sets indicated a statistically significant difference with p-values of <0.001 for all comparisons,
133 however this is reflective of the expected effect on C_t value due to dilution. Average C_t shifts of
134 1.54 ± 1.07 (ORF1ab), 1.37 ± 0.77 (N), and 2.34 ± 1.68 (S) for the asymptomatic cohort and 1.82 ± 1.01
135 (ORF1ab), 1.62 ± 0.48 (N), and 3.10 ± 1.37 (S) for the symptomatic cohort was observed. Independent t-
136 test did not show a statistically significant C_t shift between the asymptomatic and symptomatic cohorts
137 with p-values of 0.306, 0.147, and 0.052 for ORF1ab, N, and S genes, respectively (Figure 1g). Each
138 negative pool reported negative and were not deconvoluted.

139 **Discussion:**

140 This study sought to confirm SARS-CoV-2 infections that cause mild immune responses proliferate to
141 similar extents as those that elicit severe cases of COVID-19, which enables equal probability of
142 detection in RT-qPCR assay. Furthermore, the TaqMan™ multiplex assay identified each positive sample
143 in pools of five with minimal loss of sensitivity. Prevalence of SARS-CoV-2 variants, apparent by S gene
144 target loss, has increased by an order of magnitude since November 2020 at the LSTC and cases
145 represented 7% of asymptomatic and 20% of symptomatic cases in the sample size for this study [8]. It is
146 important to note, significant dilution effects observed in all genes was a result of interpreting one
147 positive per pool of five and may indicate a limitation of the experimental design due to probability of
148 more than one positive per pool in practice [9]. Thus, the practical significance observed by the average

149 C_t shifts and negligible impact to qualitative agreement supports retention of RT-qPCR sensitivity at a
150 minimum.

151 This strategy of increased extraction and elution volumes for group tests reported absolute qualitative
152 agreement to the deconvoluted counterpart, including a 1/3 gene positive case, and produced a more
153 conserved C_t shift [7,9]. Since symptomatic subjects tend to have a significantly higher prevalence of
154 COVID-19 in a pandemic setting, from a resource efficiency standpoint, it is advisable to consider pooling
155 samples when testing subjects who are non-symptomatic such as in vaccinated populations, where the
156 prevalence rates are expected to be significantly lower.

157 **Ethical Statement:**

158 This work was performed under Northeastern University Office of Human Subject Research Protection
159 (HSRP) IRB approval.

160 **Conflicts of Interest:**

161 The authors declare no conflict of interest.


162 **Acknowledgements:**

163 The authors would like to acknowledge the efforts of the LSTC technical staff, including M.K., R.M. who
164 made contributions to this work.


165 **References:**

- 166 1. Fiore VG, DeFelice N, Glicksberg BS, Perl O, Shuster A, Kulkarni K, O'Brien M, PISAURO MA, Chung
167 D, Gu X. 2021. Containment of COVID-19: Simulating the impact of different policies and testing
168 capacities for contact tracing, testing, and isolation. *PLoS One* 16:e0247614.
169 doi:10.1371/journal.pone.0247614
- 170 2. Long QX, Jia YJ, Wang X, Deng HJ, Cao XX, Yuan J, Fang L, Cheng XR, Luo C, He AR, Tang XJ, Hu JL,
171 Hu Y, Tang N, Cai XF, Wang DQ, Hu J, Qiu JF, Liu BZ, Chen J, Huang AL. 2021. Immune memory in
172 convalescent patients with asymptomatic or mild COVID-19. *Cell Discov* 7:18
- 173 3. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, Hu JL, Xu W, Zhang Y, Lv FJ, Su K, Zhang F, Gong J,
174 Wu B, Liu XM, Li JJ, Qiu JF, Chen J, Huang AL. 2020. Clinical and immunological assessment of
175 asymptomatic SARS-CoV-2 infections. *Nat Med* 26:1200-1204
- 176 4. Wang R, Chen J, Hozumi Y, Yin C, Wei GW. 2020. Decoding Asymptomatic COVID-19 Infection
177 and Transmission. *J Phys Chem Lett* 11:10007-10015.
- 178 5. Singanayagam A, Patel M, Charlett A, Lopez Bernal J, Saliba V, Ellis J, Ladhani S, Zambon M,
179 Gopal R. 2020. Duration of infectiousness and correlation with RT-PCR cycle threshold values in
180 cases of COVID-19, England, January to May 2020. *Euro Surveill* 25.
- 181 6. Praharaj I, Jain A, Singh M, Balakrishnan A, Dhodapkar R, Borkakoty B, Ashok M, Das P, Biswas D,
182 Kalawat U, Turuk J, Sugunan AP, Prakash S, Singh AK, Barathidasan R, Subhadra S, Sabat J,
183 Manjunath MJ, Kanta P, Mudhigeti N, Hazarika R, Mishra H, Abhishek K, Santhalembi C, Dikhit
184 MR, Vijay N, Narayan J, Kaur H, Giri S, Gupta N. 2020. Pooled testing for COVID-19 diagnosis by
185 real-time RT-PCR: A multi-site comparative evaluation of 5- & 10-sample pooling. *Indian J Med*
186 *Res* 152:88-94.
- 187 7. Abdalhamid B, Bilder CR, Garrett JL, Iwen PC. 2020. Cost Effectiveness of Sample Pooling to Test
188 for SARS-CoV-2. *J Infect Dev Ctries* 14:1136-1137.

- 189 8. Bal A, Destras G, Gaymard A, Stefic K, Marlet J, Eymieux S, Regue H, Semanas Q, d'Aubarede C,
190 Billaud G, Laurent F, Gonzalez C, Mekki Y, Valette M, Bouscambert M, Gaudy-Graffin C, Lina B,
191 Morfin F, Josset L, Group CO-DHS. 2021. Two-step strategy for the identification of SARS-CoV-2
192 variant of concern 202012/01 and other variants with spike deletion H69-V70, France, August to
193 December 2020. Euro Surveill 26.
- 194 9. Alcoba-Florez J, Gil-Campesino H, García-Martínez de Artola D, Díez-Gil O, Valenzuela-Fernández
195 A, González-Montelongo R, Ciuffreda L, Flores C. 2021. Increasing SARS-CoV-2 RT-qPCR testing
196 capacity by sample pooling. Int J Infect Dis 103:19-22.



199



200

201 **Figure 1:** Pairwise comparisons of pooled and deconvoluted samples for each gene target (ORF1ab, N, and
 202 S) from Asymptomatic (*a,b,c*) and Symptomatic cohorts (*d,e,f*); means indicated by dashed intersects. Box-
 203 and-whisker plot describing C_t shift for each gene from each cohort; bars are CI.95; ranges marked; p-
 204 values annotated (*g*).